{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:08:35Z","timestamp":1792804115150,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"name":"Seqirus Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Influenza leads in preventable infection-related hospitalization in nursing home (NH) residents. The adjuvanted trivalent influenza vaccine (aTIV) is more immunogenic than similarly dosed nonadjuvanted trivalent influenza vaccine (TIV), and observational studies suggest aTIV better prevents hospitalizations in older adults. We prospectively tested this in an NH setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>NHs with \u226550 long-stay residents aged \u226565 years were randomized to offer aTIV or TIV for residents for the 2016\u20132017 influenza season. Using intent-to-treat resident-level analysis with Cox proportional hazards regression models adjusted for clustering by facility and a priori baseline covariates (eg, age, heart failure, and facility-level characteristics), we assessed relative aTIV:TIV effectiveness for hospitalization (ie, all-cause, respiratory, and pneumonia and influenza [P&amp;I]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We randomized 823 NHs, housing 50 012 eligible residents, to aTIV or TIV. Residents were similar between groups by age (mean, ~79 years), heart failure, lung disease, and influenza and pneumococcal vaccine uptake, except aTIV homes housed fewer Black residents (14.5 vs 18.9%). Staff vaccine uptake was similar (~55%). P&amp;I and all-cause resident hospitalization rates were lower (adjusted HR [aHR], .80 [95% CI, .66\u2013.98; P = .03] and .94 [.89\u2013.99; P = .02], respectively) for aTIV versus TIV, while the respiratory hospitalization rate was similar, in a season where vaccine effectiveness was considered poor.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>aTIV was more effective than TIV in preventing all-cause and P&amp;I hospitalization from NHs during an A\/H3N2-predominant season when TIV was relatively ineffective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02882100.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1233","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T03:51:34Z","timestamp":1597809094000},"page":"e4237-e4243","source":"Crossref","is-referenced-by-count":36,"title":["Cluster-randomized Trial of Adjuvanted Versus Nonadjuvanted Trivalent Influenza Vaccine in 823 US Nursing Homes"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-0431","authenticated-orcid":false,"given":"Kevin W","family":"McConeghy","sequence":"first","affiliation":[{"name":"Center on Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island, USA"},{"name":"School of Public Health, Brown University, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Edward","family":"Davidson","sequence":"additional","affiliation":[{"name":"Insight Therapeutics, LLC, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Canaday","sequence":"additional","affiliation":[{"name":"Louis Stokes Veterans Administration Center, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Han","sequence":"additional","affiliation":[{"name":"Insight Therapeutics, LLC, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Saade","sequence":"additional","affiliation":[{"name":"Louis Stokes Veterans Administration Center, Cleveland, Ohio, USA"},{"name":"Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Mor","sequence":"additional","affiliation":[{"name":"Center on Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island, USA"},{"name":"School of Public Health, Brown University, Providence, Rhode Island, USA"},{"name":"Center for Gerontology and Healthcare Research, Brown University, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gravenstein","sequence":"additional","affiliation":[{"name":"Center on Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island, USA"},{"name":"School of Public Health, Brown University, Providence, Rhode Island, USA"},{"name":"Center for Gerontology and Healthcare Research, Brown University, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"2021121011180711600_CIT0001","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"2021121011180711600_CIT0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"2021121011180711600_CIT0003","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(17)30235-7","article-title":"Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial","volume":"5","author":"Gravenstein","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2021121011180711600_CIT0004","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.vaccine.2013.07.059","article-title":"The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly","volume":"31","author":"Van Buynder","year":"2013","journal-title":"Vaccine"},{"key":"2021121011180711600_CIT0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/aje\/kws313","article-title":"Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy","volume":"176","author":"Mannino","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2021121011180711600_CIT0006","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/21645515.2017.1398872","article-title":"Feasibility of a cluster-randomized influenza vaccination trial in U.S. nursing homes: lessons learned","volume":"14","author":"Gravenstein","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2021121011180711600_CIT0007","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1475-6773.2010.01194.x","article-title":"The residential history file: studying nursing home residents\u2019 long-term care histories","volume":"46","author":"Intrator","year":"2011","journal-title":"Health Serv Res"},{"key":"2021121011180711600_CIT0008","author":"Centers for Medicare & Medicaid Services, Department of Health and Human Services"},{"key":"2021121011180711600_CIT0009","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.jamda.2019.08.030","article-title":"The minimum data set agitated and reactive behavior scale: measuring behaviors in nursing home residents with dementia","volume":"20","author":"McCreedy","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"2021121011180711600_CIT0010","author":"Therneau","year":"2020"},{"key":"2021121011180711600_CIT0011","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the cox model","author":"Therneau","year":"2000"},{"key":"2021121011180711600_CIT0012","author":"Centers for Disease Control and Prevention"},{"key":"2021121011180711600_CIT0013","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/cid\/ciy775","article-title":"Influenza vaccine effectiveness in the United States during the 2016-2017 season","volume":"68","author":"Flannery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121011180711600_CIT0014","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.15585\/mmwr.mm6638a1","article-title":"Influenza vaccination coverage among health care personnel\u2014United States, 2016-17 influenza season","volume":"66","author":"Black","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121011180711600_CIT0015","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1532-5415.2009.02402.x","article-title":"Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial","volume":"57","author":"Lemaitre","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"2021121011180711600_CIT0016","article-title":"Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial","author":"Cowling","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121011180711600_CIT0017","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the safety and immunogenicity of an MF59\u00ae-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"2021121011180711600_CIT0018","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2014.07.077","article-title":"Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study","volume":"32","author":"Spadea","year":"2014","journal-title":"Vaccine"},{"key":"2021121011180711600_CIT0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.vaccine.2019.10.032","article-title":"Protection provided by influenza vaccine against influenza-related hospitalisation in \u226565 year olds: early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018\/19","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine"},{"key":"2021121011180711600_CIT0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/14760584.2019.1627206","article-title":"Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017-2018 season","volume":"18","author":"Bella","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2021121011180711600_CIT0021","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14760584.2019.1622418","article-title":"Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro\/cardiovascular events in the elderly","volume":"18","author":"Lapi","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"2021121011180711600_CIT0022","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/S0950268805003936","article-title":"Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy","volume":"133","author":"Iob","year":"2005","journal-title":"Epidemiol Infect"},{"key":"2021121011180711600_CIT0023","doi-asserted-by":"crossref","first-page":"668","DOI":"10.15585\/mmwr.mm6625a3","article-title":"Update: influenza activity in the United States during the 2016-17 season and composition of the 2017-18 influenza vaccine","volume":"66","author":"Blanton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021121011180711600_CIT0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14760584.2020.1709827","article-title":"In-depth phylogenetic analysis of the hemagglutinin gene of influenza A(H3N2) viruses circulating during the 2016-2017 season revealed egg-adaptive mutations of vaccine strains","volume":"19","author":"Galli","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"2021121011180711600_CIT0025","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/s41598-019-39276-1","article-title":"Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018","volume":"9","author":"Jorquera","year":"2019","journal-title":"Sci Rep"},{"key":"2021121011180711600_CIT0026","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59(\u00ae) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"2021121011180711600_CIT0027","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"2021121011180711600_CIT0028","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3947\/ic.2013.45.2.159","article-title":"Fluad\u00ae-MF59\u00ae-adjuvanted influenza vaccine in older adults","volume":"45","author":"Tsai","year":"2013","journal-title":"Infect Chemother"},{"key":"2021121011180711600_CIT0029","author":"Centers for Medicare & Medicaid Services"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1233\/33851127\/ciaa1233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4237\/41608210\/ciaa1233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4237\/41608210\/ciaa1233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T11:34:08Z","timestamp":1639136048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e4237\/5901187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,3]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1233","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,9,3]]}}}